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BACKGROUND: A large proportion of cancer patients are estimated to use herbal medicines, but data to substantiate this are lacking.
This study aimed to investigate the prevalence of herbal medicine use among cancer patients in the West Midlands, and determine
the characteristics predicting herbal medicine use.
METHODS: A cross-sectional survey of oncology patients (n¼1498) being followed up at a hospital in Coventry was undertaken.
Recipients were asked about herbal medicine use since their cancer diagnosis, and the association between sociodemographic
and cancer-related characteristics and herbal medicine use was evaluated.
RESULTS: A total of 1134 responses were received (75.7%). The prevalence of herbal medicine use was 19.7% (95% CI: 17.4–22.1;
n¼223). Users were more likely to be affluent, female, and aged under 50 years. Usage increased with time since cancer diagnosis
(X
2 for trend¼4.63; P¼0.031). A validation data set, derived from a survey of oncology patients in Birmingham (n¼541) with
differing socioeconomic characteristics showed no significant difference in estimated prevalence (16.6%; 95% CI: 11.9–22.2).
CONCLUSION: A substantial number of people with cancer are likely to be taking herbal medicines. Understanding the self-medication
behaviours of these individuals is essential if health-care professionals are to support treatment adherence and avoid unwanted
pharmacological interactions.
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Between 9 and 81% of cancer patients are said to use at least
one type of complementary or alternative therapy after their
cancer diagnosis (Ernst, 2000; Catt et al, 2006). In particular, self-
medication with herbal medicines and other ‘natural’ substances is
widespread and increasing in the United Kingdom (Werneke et al,
2004a; Astin et al, 2006). It has been estimated that a large
proportion of patients with cancer use herbal medicines. These
may be taken to prevent or relieve some of the symptoms of
the cancer itself (Ali and Hussain-Gambles, 2005); to help alleviate
some of the side effects from cancer treatments, such as
radiotherapy or chemotherapy (Vickers et al, 2006); to treat an
associated condition, such as anxiety or depression, or to provide
a sense of control or a feeling of active involvement in cancer
treatment (Verhoef et al, 1999). However, estimates of the
prevalence of herbal medicine use are inconsistent (varying from
3 to 25% of cancer patients), and the quality and scope of existing
studies are limited (Ernst and Cassileth, 1998; Gratus et al, 2009a).
Research typically focuses on restricted patient cohorts and
specific tumour sites; includes small numbers of participants,
and uses heterogeneous methodologies and definitions of herbal
medicines, which make it difficult to assess the precise extent of
herbal medicine use by cancer patients (Crocetti et al, 1998).
Herbal medicines are also frequently subsumed under the broader
heading of complementary and alternative medicines, and their
use assessed alongside other therapies, such as aromatherapy,
reflexology, meditation, acupuncture, and homeopathy (Downer
et al, 1994; Corner et al, 2006).
Among cancer patients, users of herbal medicines tend to be
female, younger, and have higher socioeconomic status than non-
users (Harris et al, 2003). Disease-related factors, such as the type
of cancer, stage of disease, and disease duration have also been
found to be significant predictors of herbal medicine use (Miller
et al, 1998), with women with breast cancer most likely to use
herbal medicines in comparison with the general population, and
compared with those with other cancer types (Morris et al, 2000).
However, studies of breast cancer patients and herbal medicine
use constitute the majority of research literature, and may not
be representative of other cancer diagnostic groups (Molassiotis
et al, 2005).
Alongside increased interest in the use of herbal medicines
by people with cancer, there has been a rise in concern about
the safety of these treatments (Balneaves et al, 1999). Herbal
medicines are often seen as more natural, and therefore safer than
conventional treatments, and it is generally believed that they carry
little potential for harm (Corner et al, 2006; Vickers et al, 2006).
However, in some cases, herbal medicines can present significant
risks (Gratus et al, 2009a,b). They may affect adherence with
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sprescribed treatments, cause harmful interactions with conven-
tional medications, reduce treatment efficacy, or lead to adverse
events (Frye et al, 2004; Catt et al, 2006; Medicines and Healthcare
Products Regulatory Agency, 2007). A recent systematic review
of herbal medicine use by cancer patients identified 21 case
reports of toxic effects and adverse events in users of herbal
medicines (Olaku and White, 2010). As a result of the possibility
of interactions between herbal medicines and conventional treat-
ments, people with cancer are encouraged to advise health-care
professionals if they are taking any type of medication, including
herbal medicines and other supplements (Cancer Backup, 2010),
although studies suggest that few patients do so (Corner et al, 2006).
Given the potential risks, and the lack of data to substantiate the
use of herbal medicines by cancer patients in the United Kingdom,
there is a need to better understand the prevalence of herbal
medicine use among cancer patients, as well as improving
knowledge of which herbal medicines patients use. This is an
important first step in the development of accessible, authoritative,
and independent information resources about herbal medicines
and cancer, which are currently lacking in the United Kingdom
(Gratus et al, 2009b). The aim of this study was to investigate the
prevalence of herbal medicine use among people with cancer in the
West Midlands, and to determine the sociodemographic and
cancer-related characteristics that may predict herbal medicine use
within this group.
MATERIALS AND METHODS
Study design and setting
This study used a cross-sectional survey, distributed by post,
to oncology patients being followed up at University Hospitals
Coventry and Warwickshire NHS Trust (UHC&W).
Participants and recruitment
Subsequent to securing permission from consultants responsible for
the care of patients, the hospital information system was interrogated
to identify a sample of eligible patients aged 18 and over, at least 6
months and no 45 years after a diagnosis of invasive cancer
(between 1 April 2004 and 30 June 2009), who had been treated with
curative intent. A total of 1507 potential participants were identified.
The responsible consultant examined the list of potential participants
to verify that the patient had been treated for invasive cancer and
had been diagnosed within the specified time frame. Patients known
to be terminally ill, or whom the consultant believed may be
distressed by receipt of the survey for any other reason, were
excluded from the sample to minimise the possibility of distress, as
were any individuals whose records did not indicate a consultant;
duplicate records; those for whom a valid postal address could not be
identified, and those who had died in the period between sample
identification and survey mailing.
After exclusions had been made, 1498 eligible patients were sent a
letter of invitation, a patient information sheet and a survey, to be
returned to the research team at University of Birmingham via a
FREEPOST envelope, also enclosed. This sample size assumed
a prevalence of herbal medicine use among cancer patients of
between 7 (Corner et al, 2006) and 13% (Harrison et al,2 0 0 4 ) ,a n d
that a 60% response rate would yield 900 responses. This sample
would be of sufficient size to determine the overall prevalence of
herbal medicine use among respondents with a precision of 2%
(95% confidence interval). Survey recipients who had not responded
to the initial mailing after 2 weeks received one reminder.
Survey
Survey content was informed by the findings of a systematic review
of the literature relating to herbal medicine use by cancer patients
in the United Kingdom (Gratus et al, 2009a). The survey included
closed questions on sociodemographic characteristics (age, gender,
and ethnicity), cancer-related characteristics (year of diagnosis),
and a number of categorical (yes/no response) questions relating
to the use of herbal medicines, vitamin/mineral supplements and
homeopathic remedies; the sources through which herbal
medicines were obtained by users (e.g., bought on the high street,
from a herbal medicine practitioner, purchased via the Internet),
and the use of specific herbal medicines since diagnosis, detailed
in a pre-coded ‘tick-list’, derived from a review of the most
commonly cited herbal medicines from existing research literature.
Patients were able to select multiple herbal medicines if they had
used more than one. They were also able to list any additional
herbal medicines that they had used since diagnosis, which were
not included in the pre-coded list, using a free-text response box.
Data analysis
Analysis focused on the sociodemographic and cancer-related
characteristics of respondents, and their association with herbal
medicine use. In addition to the data obtained from respondents
via their survey responses, anonymised hospital records for each
respondent were used to derive information related to cancer type,
classified according to International Classification of Diseases
(ICD-10) categories for invasive cancer (World Health Organiza-
tion, 1994), and postcode data were used to derive a deprivation
score, which was converted into a deprivation quartile using the
2007 Indices of Multiple Deprivation: quartile 1¼most affluent;
quartile 4¼most deprived (Department of Communities and Local
Government, 2007).
An individual was defined as a herbal medicine user if they
answered ‘yes’ to the question: ‘have you used herbal remedies
since your cancer was diagnosed?’ and/or gave a positive response
to any question asking about herbal medicine purchasing, and/or
indicated the use of a specific herbal medicine from the pre-coded
list or via the free-text response box. Free-text responses were
coded and analysed in the same way as herbal medicines indicated
in the tick-list. Chi-squared tests and binary logistic regression
were used to compute bivariate and multivariate odds ratios (ORs)
to evaluate the association between sociodemographic and cancer-
related characteristics and herbal medicine use, and to assess the
factors predictive of herbal medicine use by patients with cancer.
In order to test for responder bias, age, gender, ethnicity,
deprivation, and time since diagnosis distributions for respon-
dents and non-respondents were compared using w
2 tests.
Prevalence rates of herbal medicine use were age and gender
standardised to the cancer patient population in England using the
2006 cancer registration statistics (Office for National Statistics,
2006). All data were analysed using SPSS (version 15.0, SPSS Inc.,
Chicago, IL, USA).
Validation data set
As the survey population was identified from the records of one
hospital only, the survey was repeated on a smaller scale at another
hospital in Birmingham (541 patients mailed), in order to validate
the rates of herbal medicine use identified from survey respondents
treated at UHC&W and assess the wider generalisability of the
findings. Patients were identified at the participating hospital in
Birmingham in the same way as for the larger survey, according to
the same eligibility criteria, and received the same survey and study
literature; however, non-responders did not receive a reminder.
RESULTS
Of 1498 surveys distributed, 27 (1.8%) were returned blank,
indicating that the recipient did not wish to receive a reminder. A
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sfurther 337 survey recipients (22.5%) did not respond to either the
initial or reminder mailings, giving a total of 1134 useable
responses (response rate 75.7%), Figure 1.
Some statistically significant differences were found between the
sociodemographic and cancer-related characteristics of responders
and non-responders. Those in the youngest age group (o50 years
old) were significantly less likely to respond than those in older age
groups (X
2¼21.28; P¼o0.0001), and those of non-White
ethnicity were less likely to respond than those in the White
ethnic group (X
2¼105.48; P¼o0.0001). Finally, those in the most
deprived deprivation quartiles were significantly less likely to
respond to the survey than those in more affluent quartiles
(X
2¼45.61; P¼o0.0001). There were no significant differences
between responders and non-responders on the basis of gender
(X
2¼1.87; P¼0.172) or the number of years since a patient had
received their diagnosis of cancer (X
2¼1.12; P¼0.571).
Characteristics of respondents
The sociodemographic and cancer-related characteristics of
respondents are shown in Table 1. The majority of respondents
were female (n¼821; 72.4%), and in the White ethnic group
(n¼1078; 95.1%). Patients aged between 60 and 69 years old
constituted the largest group (n¼382; 33.7%), with those aged
under 50 forming the smallest respondent group (n¼188; 16.6%).
Patients in the two most affluent deprivation quartiles (quartiles 1
and 2) constituted 60.3% of respondents (n¼681), compared with
15.6% of respondents (n¼176) in the most deprived quartile.
With regard to cancer-related characteristics, the greatest propor-
tion of respondents had received their diagnosis of cancer between
Table 1 Characteristics of respondents, herbal medicine use by characteristic and predictors of herbal medicine use
Characteristic
Respondents
(%)
Herbal
medicine
users (%)
Bivariate
OR (95% CI);
significance
c
Multivariate
OR (95% CI);
significance
Deprivation
a
Affluent 681 (60.3) 144 (21.1) 1.7 (1.1–2.7); 0.027 1.7 (1.0–2.7); 0.038
More deprived 273 (24.2) 55 (20.1) 1.6 (0.9–2.6); 0.079 1.5 (0.9–2.6); 0.139
Most deprived 176 (15.6) 24 (13.6) Reference Reference
Gender
Female 821 (72.4) 183 (22.3) 1.9 (1.4–2.8); o0.0001 2.2 (1.1–4.5); 0.031
Male 313 (27.6) 40 (12.8) Reference Reference
Age group
o50 188 (16.6) 43 (22.9) 1.6 (1.0–2.5); 0.042 1.6 (1.0–2.6); 0.042
50–59 244 (21.5) 61 (25.0) 1.8 (1.2–2.7); 0.006 1.8 (1.2–2.8); 0.008
60–69 382 (33.7) 69 (18.1) 1.2 (0.8–1.8); 0.39 1.2 (0.8–1.8); 0.391
70+ 320 (28.2) 50 (15.6) Reference Reference
Ethnic group
White 1078 (95.1) 212 (19.7) 1.0 (0.5–1.9); 0.997 1.1 (0.5–2.2); 0.811
Non-White 56 (4.9) 11 (19.6) Reference Reference
Cancer type
b
Oral and respiratory 42 (3.7) 3 (7.1) 0.3 (0.1–0.9); 0.027 0.5 (0.1–1.6); 0.228
Digestive organs 160 (14.1) 26 (16.3) 0.7 (0.4–1.1); 0.078 1.1 (0.6–1.9); 0.743
Other 23 (2.0) 4 (17.4) 0.7 (0.2–2.1); 0.55 1.0 (0.3–3.7); 0.956
Thyroid and lymphoid 59 (5.2) 5 (8.5) 0.3 (0.1–0.8); 0.016 0.4 (0.2–1.1); 0.055
Female genital 114 (10.1) 28 (24.6) 1.1 (0.7–1.8); 0.672 1.2 (0.8–1.9); 0.449
Male genital 151 (13.3) 24 (15.9) 0.6 (0.4–1.0); 0.069 1.6 (0.7–3.7); 0.324
Breast 585 (51.6) 133 (22.7) Reference Reference
Years since diagnosis
o2 408 (36.0) 70 (17.2) 0.7 (0.5–0.9); 0.029 0.6 (0.4–0.9); 0.017
2–4 460 (40.6) 89 (19.3) 0.7 (0.5–1.1); 0.134 0.7 (0.5–1.0); 0.057
4+ 266 (23.5) 64 (24.1) Reference Reference
All respondents 1134 (100.0) 223 (19.7)
Age and gender standardised prevalence 16.8%
Abbreviation: OR¼odds ratio.
aDeprivation quartile could not be obtained for four respondents – OR calculated for 1130 respondents only.
bCancer types include the
following: oral and respiratory – lip, oral cavity, head and neck, pharynx, lung and intrathoracic organs; digestive organs – oesophagus, stomach, colorectal, pancreas; thyroid and
lymphoid – thyroid and other glands, lymphomas; female genital – uterus, ovaries, vulva; male genital – testicular, prostate; ‘other’ – primary bone cancer, soft tissue sarcomas,
skin, urinary tract, eye, brain and central nervous system, unknown primary cancers.
cBold entries indicate statistically significant associations.
Patients identified
(n=1507)
Patients mailed
(n=1498)
Useable response
(n=1134; 75.7%)
No useable response
(n=364; 24.3%)
- No response (n=337; 22.5%)
Excluded (n=9)
- No consultant (n=3)
- Duplicate record (n=3)
- Patient deceased (n=2)
- Incorrect address (n=1)
- Returned blank (n=27; 1.8%)
Figure 1 Consort diagram detailing surveys mailed and returned.
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s2 and 4 years before the survey mailing (n¼460; 40.6%). Patients
with breast cancer constituted the largest group according
to cancer type, accounting for over half of all respondents
(n¼585; 51.6%), followed by 14.1% with cancer related to the
digestive organs (n¼160), and male genital cancers (n¼151;
13.3%). The least represented cancer types were amalgamated and
categorised as ‘other’ cancers (n¼23; 2.0%). This included primary
bone cancer (n¼1), soft tissue sarcomas (n¼4), and cancers of the
skin (n¼3), urinary tract (n¼12), eye, brain, and central nervous
system (n¼1), and cancers of unknown origin (n¼2).
Prevalence of herbal medicine use
Across all respondents, the crude prevalence of herbal medicine
use was 19.7% (95% CI: 17.4–22.1; n¼223). The age and gender
standardised prevalence rate, calculated using the 2006 cancer
registrations statistics for England was 16.8%. A total of 282
patients had used vitamin supplements (24.9%), 258 had used
mineral supplements (22.8%), 59 had used some form of
homeopathic remedies (5.2%), and 176 had used other comple-
mentary and alternative therapies, such as aromatherapy or
massage (15.5%).
Of the herbal medicine users (n¼223), 55.2% (n¼123)
had used vitamin supplements in addition to herbal medicines,
49.3% (n¼110) had used mineral supplements as well as
herbal medicines, 21.5% (n¼48) had also used homeopathic
remedies, and 41.2% had used other complementary and
alternative therapies. Six individuals (2.7%) reported using all of
these.
Univariate analyses indicated that a greater proportion of female
respondents reported using herbal medicines than males (n¼183,
22.3% vs n¼40, 12.8%), Table 1. Respondents in the White and non-
White ethnic groups did not differ in their use of herbal medicines
(n¼212, 19.7% vs n¼11, 19.6%). Respondents in the 50–59 year
age group had the highest prevalence of herbal medicine use (n¼61;
25.0%), as did those in the two most affluent deprivation quartiles
(n¼144; 21.1%). Patients who were 44 years since diagnosis had
the highest rate of use (n¼64; 24.1%), and patients with female
genital cancers and breast cancer were most likely to be herbal
medicine users (n¼28; 24.6% vs n¼133; 22.7%).
Predictors of herbal medicine use
Binary logistic regression was used to calculate bivariate OR to
evaluate the association between sociodemographic or cancer-
related respondent characteristics and herbal medicine use
(Table 1). Users of herbal medicines were significantly more likely
to be in the two most affluent deprivation quartiles in comparison
with the most deprived quartile (quartiles 1 and 2, OR: 1.7; 95% CI:
1.1–2.7). A w
2 test for trend confirmed a decreasing likelihood
of herbal medicine use with increasing deprivation (X
2¼4.13;
P¼0.042). Females were nearly twice as likely to be herbal
medicine users as males (OR: 1.9, 95% CI: 1.4–2.8; P¼o0.0001).
Herbal medicine users were also more likely to be younger,
with patients aged under 50 years old significantly more likely
to use them than those in the 70þ age group (OR: 1.6; 95%
CI: 1.0–2.5), and those aged between 50 and 59 having the highest
likelihood of using herbal medicines (OR: 1.8; 95% CI: 1.2–2.7;
P¼0.006). There was no association between ethnic group and
herbal medicine use.
With regard to cancer-related characteristics, people with breast
cancer were most likely to be herbal medicine users, with all other
cancer types except female genital cancers having a lower usage.
Those with oral and respiratory cancers (including lip, oral cavity,
head and neck and lung cancers) were significantly less likely than
people with breast cancer to use herbal medicines (OR: 0.3; 95%
CI: 0.1–0.9), as were patients with thyroid and lymphoid cancers
(OR: 0.3; 95% CI: 0.1–0.8; P¼0.016). Usage increased with time
since diagnosis, with patients over 4 years since diagnosis the most
likely to be herbal medicine users (X
2 for trend¼4.63; P¼0.031).
Logistic regression was also used to calculate multivariate OR,
with each variable in the model controlled for all other variables.
All significant predictive factors for herbal medicine use observed
in the bivariate analysis (affluence, younger age, longer time since
diagnosis, and female gender) remained significant in the multi-
variate model, with the exception of cancer type.
Use of specific herbal medicines
All herbs detailed in the pre-coded survey list were used by at least
one individual, with the exception of Ivy (Hedera helix), Table 2.
Table 2 Frequencies of use since diagnosis for specific herbal medicines, and use by cancer type
Number of users by cancer type (%)
a
Herbal medicine
(Latin name)
Number
of users (%)
Oral and
respiratory
Digestive
organs
Thyroid and
lymphoid
Female
genital
Male
genital Breast
Other
cancers
Agnus castus (Vitex agnus castus) 4 (1.8) — — — — — 4 (100.0) —
Black cohosh (Cimicifuga racemosa) 8 (3.6) — 1 (12.5) — 3 (38.0) — 4 (50.0) —
Devil’s claw (Harpagophytum procumbens) 4 (1.8) — — — — 1 (25.0) 3 (75.0) —
Dong quai (Angelica sinensis) 2 (0.9) — — — — — 2 (100.0) —
Echinacea (Echinacea purpurea) 48 (21.5) — 3 (6.3) 2 (4.2) 9 (18.8) 5 (10.4) 29 (54.2) —
Evening primrose (Oenothera biennis) 61 (27.4) 1 (1.6) 6 (9.8) 2 (3.3) 6 (9.8) — 45 (73.8) 1 (1.6)
Garlic (Allium sativum) 43 (19.3) — 6 (14.0) 3 (7.0) 5 (11.6) 8 (18.6) 21 (48.8) —
Ginger (Zingiber officinale) 19 (8.5) — 3 (15.8) 1 (5.3) 5 (26.3) 2 (10.5) 8 (42.1) —
Gingko biloba 17 (7.6) — 3 (17.6) — 3 (17.6) 3 (17.6) 8 (47.1) —
Ginseng (Panax ginseng) 14 (6.3) — 1 (7.1) — 2 (14.3) 3 (21.4) 8 (57.1) —
Ivy (Hedera helix) 0 (0.0) — — — — — — —
Milk thistle (Silybum marianum) 16 (7.2) — 3 (18.8) 1 (6.3) 3 (18.8) 1 (6.3) 8 (50.0) —
Mistletoe (Viscum album) 6 (2.7) — 3 (50.0) — 1 (16.7) — 2 (33.3) —
Red clover (Trifolium pratense) 5 (2.2) — 1 (20.0) — 1 (20.0) 1 (20.0) 2 (40.0) —
Red vine leaf (Vitis vinifera) 2 (0.9) — — — — — 2 (100.0) —
Saw palmetto (Serenoa serrulata) 3 (1.3) — — — — 3 (100.0) — —
St John’s Wort (Hypericum perforatum) 6 (2.7) — 2 (33.3) — 1 (16.7) — 2 (33.3) 1 (16.7)
Valerian (Valeriana officinalis) 12 (5.4) — 1 (8.3) — 2 (16.7) 2 (16.7) 6 (50.0) 1 (8.3)
Wild yam (Dioscorea villosa) 2 (0.9) — — — — — 2 (100.0) —
Willow (Salix alba) 2 (0.9) — — — — — 2 (100.0) —
Any herbal medicine 274 1 (0.4) 33 (12.0) 9 (3.3) 41 (15.0) 29 (10.6) 158 (57.7) 3 (1.1)
aPercentages refer to the proportion of users of each herb from within each cancer type.
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sEvening Primrose (Oenothera biennis) was the most frequently
used herb (n¼61; 27.4%), followed by Echinacea (Echinacea
purpurea)( n¼48; 21.5%) and Garlic (Allium sativum) (n¼43;
19.3%). Breast cancer patients were the most likely to use each of
the specified herbs, constituting 100% of users of Agnus castus
(Vitex agnus castus), Dong quai (Angelica sinensis), Red vine leaf
(Vitis vinifera), Wild Yam (Dioscorea villosa), and Willow (Salix
alba). Of the other herbs, only Saw palmetto (Serenoa serrulata)
was used exclusively by patients within one cancer type – in this
case, all users (n¼3) were in the male genital cancer group.
Patients were also given the opportunity to cite the use of other
herbal medicines not detailed in the pre-coded list. Nineteen
additional herbal medicines were reported in this way, of which only
six were used by more than one individual: herbal teas (n¼14); Aloe
vera (Aloe barbadensis), (n¼8); Arnica (Arnica montana), (n¼6);
Starflower (Borago officinalis), (n¼4); Sage (Salvia officinalis),
(n¼3), and Turmeric (Curcuma longa), (n¼3).
Where herbal medicines were obtained
The majority of herbal medicine users reported obtaining their herbal
medicines from high street stores and supermarkets (n¼151; 67.7%).
Recommendation by a health-care professional was a frequent source
of information (n¼52; 23.3%), as was purchase of herbal medicines
from the Internet or through mail order (n¼51; 22.9%). Users were
less likely to obtain herbal medicines following a consultation with a
herbal practitioner; taken together, 18 unique individuals had
consulted a practitioner of Western herbal medicine, Chinese/
Ayurvedic herbal medicine, or a practitioner from another herbal
medicine tradition (8.1%), Table 3.
Validation data set
To validate the prevalence estimates for herbal medicine use
obtained from patients of UHC&W, a further small-scale survey
was undertaken involving people with cancer being followed up at
a hospital in Birmingham. In all, 217 individuals responded to this
survey from 541 mailed (response rate 40.1%). Respondents in
Birmingham differed from respondents to the larger survey with
regard to a number of characteristics. University Hospitals
Coventry and Warwickshire NHS Trust respondents were sig-
nificantly more likely to be female than those from Birmingham
(OR: 1.5; 95% CI: 1.3–1.7; P¼o0.0001). They were also twice as
likely to be in the more affluent deprivation quartiles (OR: 2.1; 95%
CI: 1.7–2.6; P¼o0.0001), and were a younger population
(X
2¼17.56; P¼0.001). Respondents from UHC&W were less
likely to be in the non-White ethnic group than those from
Birmingham (OR: 0.5; 95% CI: 0.3–8.2; P¼0.006).
The prevalence of herbal medicine use in the group from
Birmingham was 16.6% (95% CI: 11.9–22.2; n¼36). Despite the
differences in the nature of the respondent populations to both
surveys, there was no statistically significant difference in the
prevalence of herbal medicine use between the two populations
surveyed (X
2¼1.11; P¼0.292).
DISCUSSION
Almost one-fifth of our survey respondents reported using herbal
medicines in the time since their diagnosis of cancer. Age and
gender standardisation of this prevalence rate to the England
cancer patient population gave a standardised prevalence estimate
of 16.8%. With around two million people in the United Kingdom
currently living with cancer, this could equate to approximately
336000 individuals with cancer who are regular users of herbal
medicines in the United Kingdom.
By focusing on herbal medicines specifically, rather than
subsuming them under the broader term of complementary and
alternative therapies, this study adds to the very limited existing
literature regarding herbal medicine use by cancer patients in the
United Kingdom (Gratus et al, 2009a). Many studies of this nature
involve small numbers of participants and so cannot provide
precise estimates of herbal medicine use (Rees et al, 2000). The
response rate for our survey was high, and the sample size was
large (75.7%; n¼1134). The findings have face validity and fit well
with other research, which has found that women, those in
younger age groups, and those who are more affluent are the most
likely subgroups of cancer patients to use herbal medicines (Ernst
and Cassileth, 1998; Harris et al, 2003; Catt et al, 2006). A large
proportion of users were likely to use other complementary and
alternative therapies in addition to herbal medicines, such as
vitamins, mineral supplements, homeopathic remedies, or other
therapies, such as aromatherapy or massage.
Although some herbal medicines are used only by those with
particular cancer types, such as Saw palmetto (Serenoa serrulata)
used exclusively by patients with male genital cancers (Olaku and
White, 2010), herbal medicines were typically used by our
respondents across a range of cancer types, suggesting that the
majority of herbs do not seem to be targeted towards specific
cancer sites, but that they may be used for a range of reasons, such
as the reduction of symptoms associated with the cancer or its
treatment, or to address associated conditions or co-morbidities.
In common with other studies, we found that women with breast
cancer are particularly likely to use herbal medicines, as are
women with genital cancers, although in the multivariate analyses,
cancer site was not a significant predictor of herbal medicine use.
This may reflect the fact that for some cancer types, there may be
limited herbal medicines available, particularly if these are being
sought to alleviate specific conditions or side effects, either when
patients are undergoing treatment or are in the post-treatment
phase. We also found that the likelihood that people with cancer
are using herbal medicines increases with time since diagnosis.
Lower rates of use in the first 2 years after diagnosis are plausible
because patients are likely to be undergoing conventional
treatments, such as radiotherapy or chemotherapy at this time.
Higher usage in the years following treatment may indicate that
patients were more likely to consider using herbal medicines to
address the long-term consequences of cancer treatment. This
suggests that there may be less of a need to be concerned about
possible harmful interactions with conventional treatments than is
often asserted (McCune et al, 2004). However, there are
documented interactions between some herbal medicines and
other conventional medicines, such as warfarin (Ali and Hussain-
Gambles, 2005) or tamoxifen (Werneke et al, 2004b), and those
taking prescribed medication for other co-morbidities may
experience harmful interactions when using herbal medicines.
Table 3 Herbal medicine users’ source of information and purchase
Source Number (%)
Taken a herbal remedy bought off the shelf in a high street
chemist, supermarket, market stall, or health store
151 (67.7)
Consulted a practitioner of Western herbal medicine and
taken prescribed herbs
8 (3.6)
Consulted a practitioner of Chinese/Ayurvedic herbal
medicine and taken prescribed herbs
9 (4.0)
Consulted a practitioner of another herbal tradition and
taken prescribed herbs
5 (2.2)
Taken a herbal remedy prescribed or recommended by
GP, hospital doctor ,or other health-care professional
52 (23.3)
Taken a herbal remedy given to you by someone else 15 (6.7)
Taken a herbal remedy bought on the internet or through
mail order
51 (22.9)
Used a herbal remedy from another source 6 (2.7)
Totals 223 (100.0)
Abbreviation: GP¼general practitioner.
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medicines and their safety and efficacy are available to both
ongoing patients and to cancer survivors. Furthermore, if patients
require further treatment, following recurrence of disease, for
example, it is possible that herbal medicine use has become
established by this time. Routine clinical questioning should
encompass herbal medicine use before all treatment episodes.
Limitations
This study had several limitations. First, prevalence surveys that
rely on patient-reported use of herbal medicines may be subject to
recall bias. This may be deliberate, in that cancer patients may not
disclose herbal medicine use, particularly if they have not told the
health-care professionals treating them about any herbal medi-
cines or supplements that they may be using (Evans et al, 2007;
Saxe et al, 2008). Recall bias may also be inadvertent, where
patients may not remember whether or not they have taken herbal
medicines since their cancer diagnosis, and consequently either
under- or over-report their herbal medicine use. With respect to
the issue of non-disclosure, patients were informed that all survey
responses would be kept confidential and that members of their
medical team would not see any of the information that they
supplied in response to the survey.
Second, responder bias may mean that we have either under- or
over-estimated the prevalence of herbal medicine use by cancer
patients in our study population. Responders to the survey were
more likely to be affluent, older, and in the White ethnic group,
although the proportion of survey respondents in the White and
non-White ethnic groups was broadly representative of the ethnic
mix of oncology patients in England (National Cancer Intelligence
Network, 2009). However, by age and gender standardising
our prevalence estimate to the England cancer patient population,
we have derived a reliable estimate of herbal medicine use by
cancer survivors.
To minimise the risk of distress, patients known to be terminally
ill or whom the responsible consultant believed could have been
distressed by receipt of the survey were excluded from the mailing.
It is possible that this group may have been more likely to use
herbal medicines to help them cope with the stress they were
experiencing, and thus we have under-estimated the overall
prevalence of herbal medicine use by cancer patients. However,
we have no evidence to support or refute this possibility.
Finally, our survey was conducted with individuals being
followed up at a single hospital, which may affect the wider
generalisability of the findings. However, alongside the benefits of
age and gender standardisation, the inclusion of comparison data
derived from repeating the survey on a smaller scale at a hospital
in Birmingham, involving a patient population with very different
sociodemographic characteristics adds validity to our findings.
This is particularly so given that there was no statistically
significant difference found between the prevalence rate from the
larger survey and the rate observed within the comparison
population (19.7%; 95% CI: 17.4–22.1 vs 16.6%; 95% CI:
11.9–22.2; P¼0.292) despite the comparison population including
a greater proportion of older patients, more males, more patients
from non-White ethnic groups, and a higher number of socio-
economically deprived patients than the population in UHC&W.
CONCLUSIONS
It is likely that a substantial number of people with cancer are
taking herbal medicines at any one time. With such a high number
of potential users and the potential for adverse effects, including
adverse drug interactions, a robust evidence base for under-
standing all aspects of herbal medicine use by those with cancer is
required. An understanding of the self-medication behaviours of
these individuals is essential if health-care professionals are to
support treatment adherence and avoid unwanted pharmacological
interactions and compromised treatment efficacy. Health profes-
sionals need to be aware of which herbal medicines are being taken
by their patients. The provision of relevant educational resources
for both patients and health professionals is required.
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